Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · September 27, 2024

ESMO 2024: Adjuvant Durvalumab Significantly Improved Survival in Limited-Stage SCLC

The PD-L1 inhibitor extended overall survival by 22.4 months compared with placebo

PracticeUpdate Editorial Team

 

Further Reading